Newsroom | 16585 results

LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--HAYA Therapeutics to Present on RNA-guided Regulatory Genome Platform at the Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)...

DUBLIN--(BUSINESS WIRE)--The "Cone Rod Dystrophy Market: Analysis By Type, By Treatment Type, By End User, By Region Size and Trends - Forecast up to 2030" has been added to ResearchAndMarkets.com's offering. As of 2024, the global cone rod dystrophy market was valued at USD 131.29 million and is anticipated to reach USD 177.59 million by 2030. This growth, at a projected CAGR of 5.33% from 2025 to 2030, is underpinned by increasing awareness of genetic disorders and a rising need for effective...

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $73.5 million Core Revenue1 grew 16% year-over-year to $73.5 million GAAP loss of $11.5 million, or ($0.37) per share Non-GAAP income of $1.2 million, o...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. BofA Securities Health Care Conference, Las Vegas Fireside chat on Wednesday, May 14, 2025 at 1:40 p.m. ET (10:40 a.m. PT) The webcast can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.co...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $707 million for the first quarter ended March 31, 2025, compared to $638 million for the same period of 2024. “Our strong first quarter results pave the way for 2025 to mark our most transformative year yet,” said Kevin Conroy, chairman and CEO. “The Exact Sciences team just launched two innovative tests: Cologua...

ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos wins ACC.25 Pitch, showcasing how its Human-on-a-Chip® is accelerating drug development and reducing reliance on animal testing....

LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced the completion of the second dose cohort in its Phase 1/2 ASPIRE-FTD clinical trial. ASPIRE-FTD is evaluating multiple doses of AviadoBio’s investigational gene therapy, AVB-101, in people living with frontotemporal dementia (FTD) with GRN gene mutations (FTD-GRN). The company intends to initiate dosing...

威斯康辛州麥迪森--(BUSINESS WIRE)--(美國商業資訊)-- Promega宣布，ProDx MSI檢測試劑盒已獲得中國國家藥品監督管理局(NMPA)頒發的創新醫療器材註冊證書。該試劑盒採用螢光聚合酶鏈式反應(PCR)-毛細管電泳法，對腫瘤組織中的八個微衛星位點進行質性檢測。ProDx MSI檢測試劑盒將用於對結直腸癌的微衛星不穩定性進行特徵分析，以輔助辨識那些能從額外基因檢測中受惠從而診斷林奇症候群的病患。這一核准代表在中國為臨床實驗室提供先進診斷工具方面邁出了關鍵一步。 Promega上海分公司總經理Tom Duan表示：「這一證書是多年來致力於將這項創新技術引進中國臨床實驗室的成果。它為臨床醫生提供了一個寶貴的工具，用於生成關鍵的診斷資料，從而有助於結直腸癌的預防、改善早期診斷並提高病患的生存率。」 微衛星不穩定性分析 微衛星不穩定性是基因組不穩定性的一種形式，其成因是DNA複製過程中未糾正的錯誤導致在稱為微衛星的特定重複序列處出現過多或過少的堿基。MSI狀態用於篩查林奇症候群，這是一種遺傳性癌症易感症候群，做為結直腸癌最常見的遺傳誘因，可導致多種癌症的發病風險升高...

威斯康星州麦迪逊--(BUSINESS WIRE)--(美国商业资讯)-- Promega宣布，ProDx MSI检测试剂盒已获得中国国家药品监督管理局(NMPA)颁发的创新医疗器械注册证书。该试剂盒采用荧光聚合酶链式反应(PCR)-毛细管电泳法，对肿瘤组织中的八个微卫星位点进行定性检测。ProDx MSI检测试剂盒将用于对结直肠癌的微卫星不稳定性进行特征分析，以辅助识别那些能从额外基因检测中受益从而诊断林奇综合征的患者。这一批准标志着在中国为临床实验室提供先进诊断工具方面迈出了关键一步。 Promega上海分公司总经理Tom Duan表示：“这一证书是多年来致力于将这项创新技术引入中国临床实验室的成果。它为临床医生提供了一个宝贵的工具，用于生成关键的诊断数据，从而有助于结直肠癌的预防、改善早期诊断并提高患者的生存率。” 微卫星不稳定性分析 微卫星不稳定性是基因组不稳定性的一种形式，其成因是DNA复制过程中未纠正的错误导致在称为微卫星的特定重复序列处出现过多或过少的碱基。MSI状态用于筛查林奇综合征，这是一种遗传性癌症易感综合征，作为结直肠癌最常见的遗传诱因，可导致多种癌症的发病风险升...

BRISBANE, Calif.--(BUSINESS WIRE)--Oral presentation will showcase latest results with NanoCas, Mammoth Biosciences' first efficient ultracompact extrahepatic gene editor....